DENOSUMAB

Drug #2279

Denosumab is a human monoclonal antibody (IgG2) that targets and bind with hiogh affinity and specificity to RANK-L, Preventing activation of its receptors, rank, on the surface of osteolast precursorss and osteoclast, in this way it inhibits ostoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone, it is used for the treatment of osteoporosis. in post menopausal women. and in men with prostate cancer reciveing hormone ablation.

← Previous drug Next drug →

Primary Characteristics

It belongs to Human mono clobal antibody pharmacological group on the basis of mechanism of action.

Non-proprietary name: DENOSUMAB.

Pharmacokinetics

Elimination: plasma half-life is 25.4 days.

Indications

DENOSUMAB is primarily indicated in conditions like Bone metastasis, Myeloma, Osteoporosis in postmenopausal women, Rheumatoid arthritis.

Contraindications

DENOSUMAB is contraindicated in conditions like Hypocalcaemia, Hypersensitivity reactions.

Dosage

DENOSUMAB's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
60 mg	60 mg	—	S/C	given every 6 months
Paediatric Dosage (20kg)
0 – 0	—	—
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

DENOSUMAB is known to cause more or less tolerable side effects which are usually transient. These include Cataract, Constipation , Eczema, Pain in upper & lower extremities, Rashes , Sciatica.

Warnings / Precautions

Good oral hygine practice should be maintained during treatment with denosumab, for patient who develop osteonecrosis of jaws while on Denosumab therapy, dental surgery may excerbate the condition. It sholud not be given to patient with fructose intolerance. use with caution in patient with renal impariment or creatine clearence less than 30ml/min.

Available Brands

None recorded.

Storage Conditions

DENOSUMAB should be stored inj.

Drug Classification

1.2.4 — Disease modifying antirheumatic drugs